You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: November 16, 2024

~ Buy the KRAZATI (adagrasib) Drug Profile, 2024 PDF Report in the Report Store ~

CLINICAL TRIALS PROFILE FOR KRAZATI

✉ Email this page to a colleague

« Back to Dashboard

All Clinical Trials for krazati

Subscribe to access the full database, or Sign Up
Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT05840510 ↗	Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)	Not yet recruiting	Aadi Bioscience, Inc.	Phase 1/Phase 2	2023-05-31	This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
NCT05840510 ↗	Adagrasib in Combination With Nab-Sirolimus in Patients Wtih Advanced Solid Tumors and Non-Small Cell Lung Cancer Wtih a KRAS G12C Mutation (KRYSTAL -19)	Not yet recruiting	Mirati Therapeutics Inc.	Phase 1/Phase 2	2023-05-31	This study will evaluate the safety, MTD and/or RP2D, PK, and clinical activity of the combination of adagrasib with nab-sirolimus in patients with advanced solid tumors/NSCLC with a KRAS G12C mutation.
NCT05853575 ↗	Trial of Two Adagrasib Dosing Regimens in NSCLC With KRAS G12C Mutation (KRYSTAL 21)	Recruiting	Mirati Therapeutics Inc.	Phase 2	2023-04-05	This study will evaluate the efficacy of two dosing regimens of adagrasib (600 mg BID versus 400 mg BID) in patients with NSCLC with KRAS G12C mutation.
NCT06026410 ↗	KO-2806 Monotherapy and Combination Therapies in Advanced Solid Tumors	Recruiting	Mirati Therapeutics Inc.	Phase 1	2023-10-18	This first-in-human (FIH) dose-escalation and dose-validation/expansion study will assess KO-2806, a farnesyl transferase inhibitor (FTI), as a monotherapy and in combination, in adult patients with advanced solid tumors.
>Trial ID	>Title	>Status	>Sponsor	>Phase	>Start Date	>Summary

Clinical Trial Conditions for krazati

Condition Name

Chart
Table

Condition Name for krazati
Intervention	Trials
Metastatic Cancer	2
Advanced Cancer	2
Colorectal Cancer (CRC)	1
Malignant Neoplasm of Lung	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Condition MeSH

Chart
Table

Condition MeSH for krazati
Intervention	Trials
Neoplasms	3
Carcinoma, Renal Cell	1
Neoplasm Metastasis	1
Lung Neoplasms	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Locations for krazati

Trials by Country

Map
Table

Trials by Country for krazati
Location	Trials
United States	17
Canada	3
United Kingdom	1
Spain	1
Italy	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Trials by US State

Map
Table

Trials by US State for krazati
Location	Trials
California	3
Colorado	2
Tennessee	2
Massachusetts	1
Florida	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Progress for krazati

Clinical Trial Phase

Chart
Table

Clinical Trial Phase for krazati
Clinical Trial Phase	Trials
Phase 2	1
Phase 1/Phase 2	1
Phase 1	2
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Status

Chart
Table

Clinical Trial Status for krazati
Clinical Trial Phase	Trials
Recruiting	3
Not yet recruiting	1
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Clinical Trial Sponsors for krazati

Sponsor Name

Chart
Table

Sponsor Name for krazati
Sponsor	Trials
Mirati Therapeutics Inc.	4
Kura Oncology, Inc.	1
Incyte Corporation	1
[disabled in preview]	1
This preview shows a limited data set Subscribe for full access, or try a Trial

Sponsor Type

Chart
Table

Sponsor Type for krazati
Sponsor	Trials
Industry	7
[disabled in preview]	0
This preview shows a limited data set Subscribe for full access, or try a Trial

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.